Overcoming Cancers Resistant to HER-2 Antibodies Breaking Tolerance to Antibody-Mediated Immunotherapy Series
Coordonnateur : Bonavida Benjamin
This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies.
2. Sensitization of Trastuzumab Response by the Combination with Pentuzumab
3. Sensitization by Lapatinib of Trastuzumab Resistance
4. Sensitization by Ganetespib (HSP90 inhibitor) of Trastuzumab Resistance
5. Sensitization by Paclitaxel of Trastuzumab Resistance
6. Sensitization by Celecoxib of Trastuzumab Resistance
7. Sensitization by Emantasine (T-DM1) of Trastuzumab Resistance
8. Sensitization by Anti-apoptotic Inhibitors of Trastuzumab Resistance
9. Sensitization by Kinase Inhibitors of Trastuzumab Resistance
10. Sensitization by Vinorelbine of Trastuzumab Resistance
11. Sensitization by Fulvestrant of Trastuzumab Resistance
12. Sensitization by IFF-1 Inhibitors of Trastuzumab Resistance
13. Sensitization by Liposomal Doxorubicin of Trastuzumab Resistance
14. Sensitization by Combination of Immunotherapy and Trastuzumab
15. Sensitization by Radiotherapy of Trastuzumab Resistance
16. Sensitization by Chemotherapy of Trastuzumab Resistance
17. New Development of Targeted Anti-HER-2 Antibodies
cancer researchers; medical oncologists; clinicians; pharmacologists; translational investigators
- Provides a general summary of various sensitizing agents that can work effectively when used in combination with anti-HER2 antibodies to reverse resistance
- Offers potential underlying mechanisms by which cancer cells are either inherently resistant or become unresponsive to antibody treatment
- Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field
Date de parution : 06-2024
Ouvrage de 250 p.
19x23.3 cm
Thèmes d’Overcoming Cancers Resistant to HER-2 Antibodies :
Mots-clés :
cancer; sensitizing agents; antibody therapy; Trastuzumab; anticancer immunity; Lapatinib; Ganetespib; Paclitaxel; Celecoxib; Emantasine; Anti-apoptotic Inhibitors; Kinase Inhibitors; Vinorelbine; Fulvestrant; IFF-1 Inhibitors; Liposomal Doxorubicin; immunotherapy; radiotherapy; chemotherapy